Clinical evidence suggests that cellular immunity is involved in controlling human
immunodeficiency virus–1 (HIV-1) replication. An animal model of acquired immune deficiency …

With accumulating evidence indicating the importance of cytotoxic T lymphocytes (CTLs) in
containing human immunodeficiency virus–1 (HIV-1) replication in infected individuals, …

An effective HIV vaccine must elicit immune responses that recognize genetically diverse
viruses 1 , 2 . It must generate CD8 + T lymphocytes that control HIV replication and CD4 + T …

Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology
in newborns and adults 1 . There are no ZIKV-specific treatments or preventatives. …

Potent virus-specific cytotoxic T lymphocyte (CTL) responses elicited by candidate AIDS
vaccines have recently been shown to control viral replication and prevent clinical disease …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired
a D614G mutation early in the pandemic that confers greater infectivity and is now the …

HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus
across mucosal epithelium to infect CD4 + T cells. Although broadly neutralizing antibodies (…

The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies …

Most simian–human immunodeficiency viruses (SHIVs) bearing envelope (Env) glycoproteins
from primary HIV-1 strains fail to infect rhesus macaques (RMs). We hypothesized that …

Virus-specific CD4+ T cell responses have been shown to play a critical role in controlling
HIV-1 replication. Candidate HIV-1 vaccines should therefore elicit potent CD4+ as well as …